🇺🇸 RP-6306 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Dehydration — 3 reports (27.27%)
2. Acute Kidney Injury — 1 report (9.09%)
3. Cholecystitis — 1 report (9.09%)
4. Deep Vein Thrombosis — 1 report (9.09%)
5. Pain — 1 report (9.09%)
6. Pancreatitis — 1 report (9.09%)
7. Pleural Effusion — 1 report (9.09%)
8. Pneumonia Aspiration — 1 report (9.09%)
9. Pulmonary Oedema — 1 report (9.09%)

Source database →

Frequently asked questions

Is RP-6306 approved in United States?

RP-6306 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for RP-6306 in United States?

Canadian Cancer Trials Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.